A citation-based method for searching scientific literature

Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, Johan M Kros, Mathilde C M Kouwenhoven, Jean-Yves Delattre, Hans J J A Bernsen, Marc Frenay, Cees C Tijssen, Wolfgang Grisold, László Sipos, Roelien H Enting, Pim J French, Winand N M Dinjens, Charles J Vecht, Anouk Allgeier, Denis Lacombe, Thierry Gorlia, Khê Hoang-Xuan. J Clin Oncol 2013
Times Cited: 708







List of co-cited articles
589 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Gregory Cairncross, Meihua Wang, Edward Shaw, Robert Jenkins, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperriere, Walter Curran,[...]. J Clin Oncol 2013
664
64

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
61

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
32

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Jan C Buckner, Edward G Shaw, Stephanie L Pugh, Arnab Chakravarti, Mark R Gilbert, Geoffrey R Barger, Stephen Coons, Peter Ricci, Dennis Bullard, Paul D Brown,[...]. N Engl J Med 2016
506
28

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
28

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
27

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
Wolfgang Wick, Patrick Roth, Christian Hartmann, Peter Hau, Makoto Nakamura, Florian Stockhammer, Michael C Sabel, Antje Wick, Susanne Koeppen, Ralf Ketter,[...]. Neuro Oncol 2016
121
24

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
23

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree, Dominique Figarella-Branger, Cynthia Hawkins, H K Ng, Stefan M Pfister, Guido Reifenberger,[...]. Neuro Oncol 2021
816
22

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Jean Francais Baurain, Warren P Mason,[...]. Lancet 2017
184
20

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
J Gregory Cairncross, Meihua Wang, Robert B Jenkins, Edward G Shaw, Caterina Giannini, David G Brachman, Jan C Buckner, Karen L Fink, Luis Souhami, Normand J Laperriere,[...]. J Clin Oncol 2014
266
18

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
17

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
Daniel J Brat, Kenneth Aldape, Howard Colman, Dominique Figrarella-Branger, Gregory N Fuller, Caterina Giannini, Eric C Holland, Robert B Jenkins, Bette Kleinschmidt-DeMasters, Takashi Komori,[...]. Acta Neuropathol 2020
174
16

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Erica H Bell, Peixin Zhang, Edward G Shaw, Jan C Buckner, Geoffrey R Barger, Dennis E Bullard, Minesh P Mehta, Mark R Gilbert, Paul D Brown, Keith J Stelzer,[...]. J Clin Oncol 2020
47
34

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, Andreas von Deimling, Thierry Gorlia, Khê Hoang-Xuan, Alba A Brandes, Guy Kantor, Martin J B Taphoorn, Mohamed Ben Hassel,[...]. Lancet Oncol 2016
249
15

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Daniel J Brat, Kenneth Aldape, Howard Colman, Eric C Holland, David N Louis, Robert B Jenkins, B K Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp,[...]. Acta Neuropathol 2018
365
15

CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Kurt A Jaeckle, Karla V Ballman, Martin van den Bent, Caterina Giannini, Evanthia Galanis, Paul D Brown, Robert B Jenkins, J Gregory Cairncross, Wolfgang Wick, Michael Weller,[...]. Neuro Oncol 2021
22
63

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.
Michael Weller, Martin van den Bent, Jörg C Tonn, Roger Stupp, Matthias Preusser, Elizabeth Cohen-Jonathan-Moyal, Roger Henriksson, Emilie Le Rhun, Carmen Balana, Olivier Chinot,[...]. Lancet Oncol 2017
554
13

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wolfgang Wick, Christian Hartmann, Corinna Engel, Mandy Stoffels, Jörg Felsberg, Florian Stockhammer, Michael C Sabel, Susanne Koeppen, Ralf Ketter, Richard Meyermann,[...]. J Clin Oncol 2009
564
12

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
Gregory Cairncross, Brian Berkey, Edward Shaw, Robert Jenkins, Bernd Scheithauer, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperierre,[...]. J Clin Oncol 2006
523
12

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
M J van den Bent, D Afra, O de Witte, M Ben Hassel, S Schraub, K Hoang-Xuan, P-O Malmström, L Collette, M Piérart, R Mirimanoff,[...]. Lancet 2005
587
12

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
939
12

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
11

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.
David N Louis, Caterina Giannini, David Capper, Werner Paulus, Dominique Figarella-Branger, M Beatriz Lopes, Tracy T Batchelor, J Gregory Cairncross, Martin van den Bent, Wolfgang Wick,[...]. Acta Neuropathol 2018
183
11

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Patrick Y Wen, David R Macdonald, David A Reardon, Timothy F Cloughesy, A Gregory Sorensen, Evanthia Galanis, John Degroot, Wolfgang Wick, Mark R Gilbert, Andrew B Lassman,[...]. J Clin Oncol 2010
11

cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.
David N Louis, Pieter Wesseling, Kenneth Aldape, Daniel J Brat, David Capper, Ian A Cree, Charles Eberhart, Dominique Figarella-Branger, Maryam Fouladi, Gregory N Fuller,[...]. Brain Pathol 2020
206
11

Mechanisms and therapeutic implications of hypermutation in gliomas.
Mehdi Touat, Yvonne Y Li, Adam N Boynton, Liam F Spurr, J Bryan Iorgulescu, Craig L Bohrson, Isidro Cortes-Ciriano, Cristina Birzu, Jack E Geduldig, Kristine Pelton,[...]. Nature 2020
182
11

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Wolfgang Wick, Michael Platten, Christoph Meisner, Jörg Felsberg, Ghazaleh Tabatabai, Matthias Simon, Guido Nikkhah, Kirsten Papsdorf, Joachim P Steinbach, Michael Sabel,[...]. Lancet Oncol 2012
715
11

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
Michael Weller, Martin van den Bent, Matthias Preusser, Emilie Le Rhun, Jörg C Tonn, Giuseppe Minniti, Martin Bendszus, Carmen Balana, Olivier Chinot, Linda Dirven,[...]. Nat Rev Clin Oncol 2021
223
11

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
Martin J van den Bent, Antoine F Carpentier, Alba A Brandes, Marc Sanson, Martin J B Taphoorn, Hans J J A Bernsen, Marc Frenay, Cees C Tijssen, Wolfgang Grisold, Laslo Sipos,[...]. J Clin Oncol 2006
541
10

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Andrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, Kenneth D Aldape, Andreana L Rivera, April F Eichler, David N Louis, Nina A Paleologos, Barbara J Fisher, Lynn S Ashby,[...]. Neuro Oncol 2011
112
10

Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Kosuke Aoki, Hideo Nakamura, Hiromichi Suzuki, Keitaro Matsuo, Keisuke Kataoka, Teppei Shimamura, Kazuya Motomura, Fumiharu Ohka, Satoshi Shiina, Takashi Yamamoto,[...]. Neuro Oncol 2018
128
10

Mutational landscape and clonal architecture in grade II and III gliomas.
Hiromichi Suzuki, Kosuke Aoki, Kenichi Chiba, Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Teppei Shimamura, Atsushi Niida, Kazuya Motomura, Fumiharu Ohka,[...]. Nat Genet 2015
502
10

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Romain Appay, Caroline Dehais, Claude-Alain Maurage, Agusti Alentorn, Catherine Carpentier, Carole Colin, François Ducray, Fabienne Escande, Ahmed Idbaih, Aurélie Kamoun,[...]. Neuro Oncol 2019
57
17

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.
Quinn T Ostrom, Nirav Patil, Gino Cioffi, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2020
498
10

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Hendrikus J Dubbink, Peggy N Atmodimedjo, Johan M Kros, Pim J French, Marc Sanson, Ahmed Idbaih, Pieter Wesseling, Roelien Enting, Wim Spliet, Cees Tijssen,[...]. Neuro Oncol 2016
92
9

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.
Maarten M J Wijnenga, Pim J French, Hendrikus J Dubbink, Winand N M Dinjens, Peggy N Atmodimedjo, Johan M Kros, Marion Smits, Renske Gahrmann, Geert-Jan Rutten, Jeroen B Verheul,[...]. Neuro Oncol 2018
135
9

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Patrick J Killela, Zachary J Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A Diaz, Allan H Friedman, Henry Friedman, Gary L Gallia, Beppino C Giovanella,[...]. Proc Natl Acad Sci U S A 2013
923
9

DNA methylation-based classification of central nervous system tumours.
David Capper, David T W Jones, Martin Sill, Volker Hovestadt, Daniel Schrimpf, Dominik Sturm, Christian Koelsche, Felix Sahm, Lukas Chavez, David E Reuss,[...]. Nature 2018
9

Prognostic factors for survival in adult patients with cerebral low-grade glioma.
Francesco Pignatti, Martin van den Bent, Desmond Curran, Channa Debruyne, Richard Sylvester, Patrick Therasse, Denes Afra, Philippe Cornu, Michel Bolla, Charles Vecht,[...]. J Clin Oncol 2002
588
9

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
Robert B Jenkins, Hilary Blair, Karla V Ballman, Caterina Giannini, Robert M Arusell, Mark Law, Heather Flynn, Sandra Passe, Sara Felten, Paul D Brown,[...]. Cancer Res 2006
494
9

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
Martin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Sarah Erridge, Michael A Vogelbaum, Anna K Nowak, Jean Français Baurain,[...]. Lancet Oncol 2021
31
29

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
8

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Roger Stupp, Sophie Taillibert, Andrew Kanner, William Read, David Steinberg, Benoit Lhermitte, Steven Toms, Ahmed Idbaih, Manmeet S. Ahluwalia, Karen Fink,[...]. JAMA 2017
825
8

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
David A Reardon, Alba A Brandes, Antonio Omuro, Paul Mulholland, Michael Lim, Antje Wick, Joachim Baehring, Manmeet S Ahluwalia, Patrick Roth, Oliver Bähr,[...]. JAMA Oncol 2020
338
8

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.
Linda Douw, Martin Klein, Selene Saa Fagel, Josje van den Heuvel, Martin Jb Taphoorn, Neil K Aaronson, Tjeerd J Postma, W Peter Vandertop, Jacob J Mooij, Rudolf H Boerman,[...]. Lancet Neurol 2009
423
8

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Annika Malmström, Bjørn Henning Grønberg, Christine Marosi, Roger Stupp, Didier Frappaz, Henrik Schultz, Ufuk Abacioglu, Björn Tavelin, Benoit Lhermitte, Monika E Hegi,[...]. Lancet Oncol 2012
745
8

T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.
Sohil H Patel, Laila M Poisson, Daniel J Brat, Yueren Zhou, Lee Cooper, Matija Snuderl, Cheddhi Thomas, Ana M Franceschi, Brent Griffith, Adam E Flanders,[...]. Clin Cancer Res 2017
147
7

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Melike Pekmezci, Terri Rice, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Helen Hansen, Hugues Sicotte, Thomas M Kollmeyer, Lucie S McCoy, Gobinda Sarkar,[...]. Acta Neuropathol 2017
176
7

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Mitsuaki Shirahata, Takahiro Ono, Damian Stichel, Daniel Schrimpf, David E Reuss, Felix Sahm, Christian Koelsche, Annika Wefers, Annekathrin Reinhardt, Kristin Huang,[...]. Acta Neuropathol 2018
166
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.